Abstract
Background: Histone deacetylase (HDAC) inhibition has been found to be effective in the treatment of inflammatory bowel disease. Previous studies have reported that Cinnamyl sulfonamide hydroxamate derivatives possess non-selective HDAC inhibition.
Objective: The present study was designed to screen three selected Cinnamyl sulfonamide hydroxamate derivatives, NMJ-1, NMJ-2, and NMJ3, for in vitro anti-inflammatory response by assessing the expression of pNF-κB in lipopolysaccharide (LPS)-induced inflammatory changes on RAW 264.7 cells, and in vivo anti-inflammatory response in acetic acid (AA) and 2.4-dinitrochlorobenzene (DNCB)-induced colitis models in Wistar rats. Method: AA-induced colitis was produced in Wistar rats by intra-colonic administration of 1 ml AA. DNCBinduced colitis was produced by spraying 250 μL DNCB in acetone (20g/L) on the nape of the rats for 14 days, followed by the intracolonic administration on day 15. Drugs were administered for three days after the induction of colitis. Results: In vitro anti-inflammatory effect was observed by NMJ1 and NMJ2 through a significant decrease in pNF-κB overexpression-induced by LPS. Similar effect was observed in anti-colitis response by NMJ2 in both models by reversing the colitis-induced changes in length, weight, anti-oxidant profile and histopathology of the colon. Conclusion: NMJ2 was found to be most effective among the tested compounds as an anti-inflammatory agent in both in vitro and in vivo inflammatory studies.Keywords: Inflammatory bowel disease, cinnamyl sulfonamide hydroxamate derivatives, Sulphasalazine, 2, 4-Dinitrochlorobenzene-induced colitis, acetic acid-induced colitis, HDAC inhibitors, anti-oxidant, NF-κB.
[http://dx.doi.org/10.1002/ibd.20036 ] [PMID: 17206705]
[http://dx.doi.org/10.4137/CGast.S12731 ] [PMID: 24833941]
[http://dx.doi.org/10.1111/jgh.12751 ] [PMID: 25827798]
[http://dx.doi.org/10.1111/apt.13008 ] [PMID: 25367825]
[http://dx.doi.org/10.1186/s13020-020-0296-z ] [PMID: 32063999]
[http://dx.doi.org/10.1136/gut.2007.134650 ] [PMID: 18194985]
[http://dx.doi.org/10.1016/j.cbi.2016.05.008 ] [PMID: 27163855]
[http://dx.doi.org/10.1016/j.cbi.2015.03.015 ] [PMID: 25824412]
[http://dx.doi.org/10.1016/j.intimp.2012.10.028 ] [PMID: 23159605]
[http://dx.doi.org/10.1016/S0076-6879(84)05016-3 ] [PMID: 6727660]
[http://dx.doi.org/10.3892/br.2019.1226 ] [PMID: 31338194]
[http://dx.doi.org/10.1016/S0076-6879(94)33044-1 ] [PMID: 8015473]
[http://dx.doi.org/10.1016/j.freeradbiomed.2007.04.026 ] [PMID: 17664129]
[http://dx.doi.org/10.1016/j.it.2011.04.001 ] [PMID: 21570914]
[http://dx.doi.org/10.1016/j.tibs.2004.11.009 ] [PMID: 15653325]
[http://dx.doi.org/10.1146/annurev.immunol.14.1.649 ] [PMID: 8717528]
[http://dx.doi.org/10.1038/nrc780 ] [PMID: 12001991]
[http://dx.doi.org/10.1038/nrgastro.2015.186 ] [PMID: 26627550]
[http://dx.doi.org/10.3748/wjg.v6.i5.742 ] [PMID: 11819686]
[http://dx.doi.org/10.1159/000198104 ] [PMID: 627326]
[http://dx.doi.org/10.1074/jbc.M209572200 ] [PMID: 12419806]
[http://dx.doi.org/10.3748/wjg.v13.i7.1103 ] [PMID: 17373747]
[http://dx.doi.org/10.1053/j.gastro.2009.10.037 ] [PMID: 19879272]
[http://dx.doi.org/10.1016/j.mam.2008.08.006 ] [PMID: 18796312]
[http://dx.doi.org/10.4103/0973-1296.165991 ] [PMID: 26664018]
[http://dx.doi.org/10.4103/1319-3767.182459 ] [PMID: 27184642]